SINGAPORE'S Novena Global Healthcare has bagged US$20 million in investment from Sinopharm Capital and Cedarlake Capital Group.
The US$20 million investment will be used to grow the Singapore aesthetic healthcare firm's existing business in China and South-east Asia. This is while leveraging on Sinopharm Capital’s network and resources for its China expansion. Nelson Loh, executive chairman and co-founder of DORR Group and Novena Global Lifecare, said the company will continue to innovate and disrupt the lifecare industry around the region.
このニュースをすぐに読めるように要約しました。ニュースに興味がある場合は、ここで全文を読むことができます。 続きを読む: